CV Sciences, Inc. CVSI, a consumer wellness company specializing in hemp extracts and other science-backed, natural ingredients and products, announced its financial results for the quarter ended September 30, 2023.
Third Quarter 2023 Financial Highlights
- Q3 2023 revenue increased to $4.1 million, demonstrating a 9% growth compared to Q3 2022 and a sequential improvement from $4.0 million in Q2 2023.
- Gross margin for Q3 2023 reached 45.1%, up from 41.6% in Q3 2022 and a sequential improvement from 43.3% in Q2 2023.
- Ending Q3 2023 with a cash balance of $1.6 million, a notable increase from $0.6 million at the end of 2022.
- Positive cash flow from operations of $2.4 million in the first nine months of 2023, a significant turnaround from cash used in operations of $2.1 million in the first nine months of 2022. Cash flow from operations included an employee retention credit (ERC) under the CARES Act totaling $2.5 million.
Joseph Dowling, CEO of CV Sciences, stated: "We are very pleased with our third quarter 2023 results. In a challenging environment, our revenues of $4.1 million increased both sequentially and year-over-year. Our gross margin also improved to 45.1%, again, both a sequential and year-over-year increase."
Operating Results - Q3 2023 vs. Q3 2022
- Sales for Q3 2023 amounted to $4.1 million, a 9% increase from $3.8 million in Q3 2022, driven by a higher number of units sold and increased average sales price per unit.
- Q3 2023 operating loss improved to $0.4 million, compared to an operating loss of $0.9 million in Q3 2022, attributed to higher sales, improved gross margins, and lower operating expenses.
- Negative adjusted EBITDA for Q3 2023 was $0.4 million, an improvement from negative adjusted EBITDA of $1.2 million in Q3 2022.
"Our third quarter progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow,” said Dowling.
Price Action
CVSI's shares were trading 0.82% down at $0.0302 per share at the time of writing on Tuesday afternoon.
Read Next: How to Invest in Cannabis Stocks
Image by Morgan Housel On Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.